APA引文

Patel, K. K., Zeidan, A. M., Shallis, R. M., Prebet, T., Podoltsev, N., & Huntington, S. F. (2021). Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv.

Citação norma Chicago

Patel, Kishan K., Amer M. Zeidan, Rory M. Shallis, Thomas Prebet, Nikolai Podoltsev, and Scott F. Huntington. "Cost-effectiveness of Azacitidine and Venetoclax in Unfit Patients With Previously Untreated Acute Myeloid Leukemia." Blood Adv 2021.

MLA引文

Patel, Kishan K., et al. "Cost-effectiveness of Azacitidine and Venetoclax in Unfit Patients With Previously Untreated Acute Myeloid Leukemia." Blood Adv 2021.